Schrödinger
Builds physics-based software for molecular design and uses it in drug discovery.
Something off on this page? Send us feedback.
Profile
Sells physics-based molecular modeling software to life-science and materials-science researchers, then applies the same platform to proprietary and partnered therapeutics. Software is the larger segment, while drug discovery revenue depends on collaborations, milestones, royalties, and clinical execution.
Provides a physics-based molecular discovery platform for life-science and materials-science R&D. Software products include LiveDesign for collaboration, Maestro for modeling workflows, FEP+ for binding predictions, and Glide for docking and screening.
Applies the same computational platform inside a therapeutics group that advances proprietary programs and partnered drug discovery work. Revenue comes from software licenses and drug discovery economics such as upfront payments, milestones, royalties, and collaborator equity stakes.
Serves biopharmaceutical companies, industrial customers, academic institutions, and government laboratories worldwide. The business depends on life-sciences R&D budgets, collaboration outcomes, clinical execution, and competition from commercial vendors, academic packages, in-house biopharma tools, and AI-enabled discovery companies.
Company facts
Categories
Key statistics
Year to date +9.6% · Average volume (30d) 1.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | UBS | Initiate | Neutral | $18 | $19 | |
| Jan 7, 2026 | UBS | Target | $18 | |||
| Dec 15, 2025 | B of A Securities | Upgrade | Neutral | Buy | ||
| Sep 29, 2025 | Goldman Sachs | Target | $27 | $19 | ||
| Aug 15, 2025 | Citigroup | Downgrade | Buy | Neutral |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.41 | $0.08 | +119.3% | $47.2M | $58.9M | +24.8% | +8.60% |
| May 5, 2026Q1 FY26 | −$0.56 | −$0.81 | −44.6% | $47.6M | $58.6M | +23.2% | +0.85% |
| Feb 25, 2026Q4 FY25 | −$0.13 | $0.44 | +438.5% | $83.8M | $87.2M | +4.1% | +8.14% |
| Nov 5, 2025Q3 FY25 | −$0.75 | −$0.45 | +40.0% | $83.6M | $54.3M | −35.0% | −5.67% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $59.6M | $54.8M | $54.3M | $87.2M | $58.6M | $58.9M | |
| Gross profit | $31.1M | $26.2M | $28.0M | $57.3M | $29.5M | $32.4M | |
| Operating income | −$50.9M | −$52.9M | −$45.9M | −$17.2M | −$48.8M | −$41.5M | |
| Net income | −$59.8M | −$43.2M | −$32.8M | $32.5M | −$60.0M | $6.0M | |
| Diluted EPS | −$0.82 | −$0.59 | −$0.45 | $0.44 | −$0.81 | $0.08 | |
| Gross margin | 52.3% | 47.8% | 51.6% | 65.7% | 50.4% | 55.1% | |
| Operating margin | -85.5% | -96.6% | -84.6% | -19.7% | -83.3% | -70.6% |
Fiscal years (4-quarter sums)FY21 $137.9M · FY22 $181.0M · FY23 $216.7M · FY24 $207.5M · FY25 $255.9M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $413.7M · Total debt $108.0M · Total assets $640.4M · Shareholders' equity $329.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 74.72M · Float 57.65M · 77.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.52M | 14.08% | 13F | Aug 7, 2026 |
| Bill & Melinda Gates Foundation Trust | 6.98M | 9.34% | 13F | Aug 14, 2026 |
| Rubric Capital Management LP | 6.40M | 8.57% | 13F | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 3.79M | 5.07% | 13F | Aug 13, 2026 |
| Sumitomo Mitsui Trust Group, Inc. | 2.71M | 3.62% | 13F | Jul 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 16, 2026 | Rachit Jain | officer: EVP & CFO | −875 | $15.60 |
| Apr 16, 2026 | Rachit Jain | officer: EVP & CFO | −844 | $12.75 |
| Apr 17, 2026 | Ramy Farid | director, officer: President & CEO | −43,000 | $12.21 |
| Apr 16, 2026 | Ramy Farid | director, officer: President & CEO | −43,000 | $12.33 |
| Mar 4, 2026 | Robert Lorne Abel | officer: See Remarks | −1,300 | $12.81 |
Peers
- Cadence Design Systems
OpenEye overlaps in cloud molecular design and docking
- Certara
Model-informed drug development software and services
- Revvity
Signals software overlaps in R&D informatics and chemistry
- Simulations Plus
ADMET and PBPK modeling in model-informed drug R&D
- AbCellera Biologics
Antibody discovery platform and partner economics
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Schrödinger | $19.67 | −0.15% | $1.47B | — | — | 5.7 | +7.5% |
| Cadence Design Systems | $329.89 | −3.10% | $93.74B | 67.7 | 39.7 | 16.1 | +24.2% |
| Certara | $8.35 | −0.12% | $1.30B | — | 21.5 | 3.2 | −10.8% |
| Revvity | $127.20 | −1.25% | $14.37B | 61.3 | 22.9 | 4.9 | −1.3% |
| Simulations Plus | $18.40 | 0.00% | $371.9M | 46.0 | 21.6 | 4.5 | +7.5% |
| AbCellera Biologics | $11.37 | +0.24% | $3.47B | — | — | 52.4 | −76.3% |
| Median | 61.3 | 22.3 | 4.9 | −1.3% |